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 Behind the dramatic advance of biolo-
gic agents lies the potential for another, 
sometimes less appreciated, revolution for 
experimental medicine. Biologic agents, 
by their nature, facilitate the dissection 
of the role played by the drug ’ s target 
in the disease. Consequently, patient-
focused investigation can begin to acquire 
a level of experimental sophistication 
that, until now, has been the exclusive 
domain of mouse immunologists. Not 
only can this form of experimental med-
icine add substantially to our under-
standing of the immunopathogenesis 
of disease, but it can also aide in the 
development of new therapies. Not all 
patients respond to any given biologic 
agent, a fact that may provide clues to 
alternate mechanisms of disease, and may 
also allow us to more accurately classify 
certain diseases based on response to 
therapy. This commentary will briefl y 
discuss three aspects of the impact of 
biological therapy on experimental medi-
cine. First, that the use of agents that 
target the same molecule can have 
very diff erent therapeutic eff ects. Second, 
parallels can now be drawn between pa-
tients and corresponding animal models 
in which the same molecule is targeted. 
Finally, that widespread application of 
biological therapies to diff erent diseases 
can reveal common immunologic path-
ways (Fig. 1). 
 Dissecting disease mechanisms 
 Although a major focus of experimen-
tal medicine has been the development 
of new biological agents, dissecting the 
mechanism(s) of action of successful new 
agents is equally important. Removed 
from the regulatory and conceptual 
straightjacket of clinical trials, successful 
biologic agents are now being adminis-
tered to thousands of patients, and these 
patients represent a tremendous resource 
for experimental medicine. The block-
ade of a specifi c target protein or the 
removal of a particular cell population 
in patients provides information about 
disease processes that cannot be gleaned 
from association studies. These patient 
populations allow the disease to be ana-
lyzed in responders and nonresponders, 
both before and after the intervention. 
 Nevertheless, the prospect of un-
der standing the pathogenesis of auto-
immune disease by studying how specifi c 
biologic treatments work has not been 
a familiar mindset among the clinical 
community. This is hardly surprising 
when the list of immunomodulatory 
drugs begins with corticosteroids, drugs 
that aff ect the transcription of 20% 
of proteins expressed by lymphocytes. 
Although eff orts are being made to 
tease out the benefi cial eff ects of cor-
ticosteroids from the harmful ones 
( 1 ), it is unlikely that a particular mo-
lecular target will be identifi ed that 
explains all of its immunomodulatory 
eff ects. A similar principle applies to 
other  “ conventional ” therapies, such 
as the rheumatoid arthritis (RA) drugs 
methotrexate and sulphasalazine. We 
don ’ t know exactly how they work, 
but we know (partly as a result of edu-
cated guesswork) that they aff ect mul-
tiple immunologic pathways. The fact 
that they do work was not predicted by 
an a priori hypothesis beyond a vague 
idea of immunosuppression.  Therefore, 
it is diffi  cult to make predictions about 
which patients (or diseases) may respond 
to treatment based on an understand-
ing of the drug ’ s mechanism of action. 
There are, however, a priori hypotheses 
behind the development of biological 
agents, and these hypotheses can be 
tested. Despite this, some believe that if 
a biologic therapy is eff ective, fi guring 
out why is not a high priority. Indeed, 
the success of a particular biologic ther-
apy often leads to further intellectual 
attachment to the original immuno-
logic rationale. 
 The administration of biologic ther-
apies to patients with autoimmune dis-
eases, however, has revealed several 
surprises that illustrate the value in un-
derstanding how biologic agents work. 
For instance, it might be expected that 
targeted inhibition of a single cytokine, 
such as tumor necrosis factor (TNF), 
would yield a simple understanding of 
the role of TNF in disease pathogenesis. 
However, diff erent anti-TNF drugs can 
appear to behave as entirely separate 
agents. An excellent example is etan-
ercept (soluble TNF-  receptor) and 
infl iximab (chimeric anti – TNF-  mono-
clonal antibody), of which only the 
latter is eff ective for the treatment of 
Crohn ’ s disease ( 2, 3 ). In this infl am-
matory bowel disease, infl iximab, but 
not etanercept, induces the apoptosis of 
lamina propria T cells, which could ex-
plain the diff erential effi  cacy of the two 
agents, though other processes have also 
been implicated ( 4, 5 ). 
 In contrast, both infl iximab and etan-
ercept are eff ective in patients with RA. 
There has been much fanfare, and rightly so, heralding a revolution in the 
treatment of autoimmune disease using biologic agents — antibodies or other 
molecules that specifi cally target known mediators of disease. But not all 
patients respond to even the most successful biologic agent, which may 
provide clues about alternate disease mechanisms. Studies aimed at under-
standing the mechanism of action of biologic agents will yield signifi cant 
benefi ts for experimental medicine.
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of TNF ameliorates disease ( 9 – 11 ). Of 
interest, although arthritis cannot be in-
duced in B cell – defi cient mice, it can be 
induced (albeit mildly) in TNF- defi cient 
mice ( 12 ). Surprisingly, whereas the dem-
onstration that TNF promotes disease in 
the CIA model has been used to support 
clinical trials ( 13 ), the role of B cells in 
CIA was long considered of little rele-
vance to human therapy. The impor-
tance of B cells was also demonstrated in 
a T cell transgenic model of arthritis, in 
which no joint infl ammation occurred 
in the absence of B cells ( 14 ).
 The success of the B cell–depleting 
drug rituximab (anti-CD20 antibody) in 
treating patients with RA has provided 
proof that B cells are important in RA, 
and has lead to a reemphasis on the role 
of B cells in various experimental models 
of arthritis. So far, little is known about 
whether B cells contribute to RA patho-
genesis by producing antibodies and/or 
presenting antigen to T cells. But this 
question could be addressed by studying 
patients receiving rituximab and other 
B cell–targeting agents. The hope is that 
data generated from such studies will 
facilitate a more interactive dialogue be-
tween those studying patients and those 
studying animal models. One recent 
example of this was the administration 
of anti-CD20 to mice with CIA, which 
demonstrated that B cell depletion be-
fore, but not after, collagen adminis-
tration diminished disease severity (15). 
Whether this result provides further in-
sight into the pathogenesis of RA, or is 
simply specifi c for that experimental 
model, remains to be determined.
 Studies conducted in the past two 
decades examining the role of TNF in 
EAE have generated suffi  cient data to 
justify the use of TNF-blocking agents 
for the treatment of MS. In mice, dis-
ease severity is reduced when TNF is 
blocked using antibodies ( 16, 17 ), and 
disease is delayed in mice genetically de-
fi cient for TNF ( 18 ). In general, over-
expression of TNF exacerbates disease in 
the EAE model ( 19 ). Humans, however, 
have proven to be a diff erent story. In 
1999, a randomized, placebo-controlled 
study demonstrated that blocking TNF 
worsened disease in patients with MS 
( 20 ). TNF has a complex role in the 
models we use to identify potential tar-
gets for the treatment of human disease. 
Although the relevance of animal models 
for human disease has been much de-
bated, these models have yielded impor-
tant insights. Manipulation of mice using, 
for example, blocking antibodies and ge-
netic targeting has provided defi nitive 
answers about the role of specifi c molec-
ular targets in a given disease setting. The 
introduction of blocking antibodies for 
the treatment of human disease has al-
lowed direct comparisons to be drawn 
between patients and the corresponding 
disease models. To illustrate the inter-
relationship between experimental mod-
els and their human disease counterparts, 
we will discuss two diff erent biologic 
therapies (B cell depletion and anti-TNF 
therapy) in the context of two disease 
models, collagen-induced arthritis (CIA), 
a model of RA, and experimental aller-
gic encephalomyelitis (EAE), a model of 
multiple sclerosis (MS). 
In the CIA model, the absence of 
B cells prevents disease and the blockade 
But patients who fail to respond to one 
type of anti-TNF drug are only margin-
ally less likely to respond to a diff erent 
anti-TNF drug ( 6, 7 ) compared to “anti-
TNF naive” patients, again suggesting 
that the drugs ’ mechanism(s) of action 
diff er. Infl iximab induces the diff erenti-
ation of regulatory T cells in responsive 
patients with RA, highlighting another 
potential mechanism of action ( 8 ). Ef-
forts to discover which disease mech-
anisms are associated with a clinical 
response may help identify new thera-
peutic targets. This could also reveal ther-
apeutic biomarkers that predict clinical 
responsiveness, allowing physicians to 
target therapies only to those patients 
who are likely to respond (Fig. 1). Apart 
from being cost-eff ective, such clinical 
biomarkers would spare many patients 
the substantial risks associated with agents 
such as anti-TNF drugs. 
 One therapeutic target, two species 
 The effi  cacy of biologic therapies has also 
focused attention on the experimental 
 Figure 1.  Biologic therapy as a catalyst for experimental medicine and therapeutic advance. 
Targeted manipulation of the immune system in animal models, such as with biologic agents, has 
led to insights into disease pathogenesis and has contributed to the use of these agents in humans. 
The use of biologic agents in patients with autoimmune disease may help identify alternate disease 
mechanisms, establish biomarkers of disease, and reevaluate the pathogenesis of disease. Studies 
in humans can in turn help refi ne experimental animal models. 
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infl ammatory bowel disease exacer-
bated by an overzealous immune re-
sponse ( 32 ). 
 Although we are only at the begin-
ning of this process, studies involving bio-
logic therapies emphasize the  “ two-way 
street ” nature of experimental medicine 
in patients and studies in experimental 
animal models. There is a plethora of 
new agents arriving in the clinic that has 
been spurred on by the success of the 
early biologic agents. Experimental medi-
cine must continue to thrive in the clin-
ical setting where successful biologic 
therapies off er the prospect of great in-
sight into the mechanisms of disease. 
Inevitably, this will promote the intro-
duction of more specifi c, long-lasting, 
and perhaps less expensive therapies. Thus, 
the answer to the question of whether 
we need to know why the treatment 
works is a resounding  “ Yes! ” 
 We thank Dr. Lucy Wedderburn for critical reading 
of this commentary. 
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